Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study

BackgroundBiomarkers guiding immunotherapy in non-small cell lung cancer (NSCLC) are limited. The glucose-to-lymphocyte ratio (GLR), integrating metabolic and immune status, has shown prognostic value in several cancers but has not been systematically evaluated in patients receiving PD-1 blockade.Me...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mustafa Ersoy, Umut Kefeli, Devrim Cabuk, Ertugrul Bayram, Duygu Bayir, Oktay Bozkurt, Muslih Ürün, Ramazan Coşar, Teoman Sakalar, Emel Mutlu, Muhammet Cengiz, Elif Sahin, Pervin Sancı, Canan Yıldız, Erdem Kolemen, Ayse Cengiz, Gozde Agdas, Erkam Kocaaslan, Ezgi Turkoglu, Sedat Yıldırım, Berrak Mermeit, Anil Karakayalı, Hayati Arvas, Mehmet Mutlu, Sedat Biter, Havva Yeşil Çinkir, Mehmet H. Yücel
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2026-02-01
Colecção:	Frontiers in Immunology
Assuntos:	biomarkers glucose-to-lymphocyte ratio immune checkpoint inhibitors immunometabolism nivolumab non-small cell lung cancer
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1714533/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!